Bio Essence Corporation
BIOE
Other OTC0.27
USD
- -
- -
CIK
0001723059
ISIN
US09090C1053
CUSIP
09090C105
Return %
Stock
S&P500
1Y
145.45
18.86
3Y
-47.06
64.57
5Y
-46.00
71.65
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Yin Yan
- Full Time Employees
- 4
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 2955 Main Street Irvine CA United States of America 92618
- IPO Date
- Dec 1, 2022
- CIK
- 0001723059
- Website
- bioessencecorp.com
- Similar Companies
- Business
- Bio Essence Corporation (OTC Pink: BIOE), founded in 2000 and headquartered in Irvine, California, operates as a biotechnology and herbal health company focused on manufacturing and distributing health supplement products; it provides original equipment manufacturing (OEM) services, including compounding, encapsulation, tabletting, packaging, product development, ingredient sourcing, and testing; and serves healthcare practitioners through holistic wellness solutions such as custom formulations, online pharmacy platforms, and in-person clinics offering spa-like environments for patient care. The company targets healthcare professionals and consumers seeking herbal health, diet, nutrition, vitamin supplements, traditional Chinese medicine (TCM) herbs, anti-aging products, men's health, women's health, optic health, and sleep health offerings, with operations primarily in the United States and capabilities for international export. Bio Essence maintains an in-house R&D team augmented by partnerships with top-tier healthcare professionals and a medical advisory board to drive innovation in biotech and wellness products. In recent major changes, the company completed the sale of its subsidiaries Bio Essence Pharmaceutical Inc. and Bio Essence Herbal Essentials Inc. for $700,000 in 2024, recording a gain on the disposal of Bio Essence Herbal Essentials Inc.; dissolved other subsidiaries including Fusion Naturals and McBE Pharma to streamline operations; shifted to direct management and outsourced manufacturing while focusing on expanding its OEM business; and executed a significant debt-to-equity conversion where CEO Yin Yan received 5,000,000 shares for retiring $2,500,000 in debt. These strategic restructurings aim to enhance profitability amid financial challenges, with management planning increased sales efforts, marketing enhancements, and pursuit of additional funding or acquisition opportunities.
Bio Essence Corporation (OTCQB: BIOE) to Acquire MediFlow AI Platform, Strengthening Its Human Health and Wellness Portfolio
BIO ESSENCE CORP (OTCQB:BIOE) Announces Approval for Upgrade to the OTCQB Market, Effective February 26, 2026